Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

<p>Kaplan–Meier plot of (<b>A</b>) PFS and (<b>B</b>) OS. CI, confidence interval; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria for Solid Tumors version 1.1.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Diwakar Davar (15023480) (author)
Altres autors:	Zeynep Eroglu (19276519) (author), Mohammed Milhem (16527976) (author), Carlos Becerra (22053822) (author), Martin Gutierrez (15360052) (author), Antoni Ribas (14837278) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Hailei Zhang (20634191) (author), Srimoyee Ghosh (22053025) (author), Niranjan Yanamandra (22053022) (author), Theo Borgovan (22053031) (author), Shyam Srivats (22053825) (author), Angela Waszak (22053034) (author), Arindam Dhar (15016280) (author), Patricia LoRusso (15134565) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Immunotherapy Antibody immunotherapy Checkpoint blockade Lung Cancer Oncogenes & Tumor Suppressors PD-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!